{'fraction_non_alphanumeric': 0.02003338898163606, 'fraction_numerical': 0.00667779632721202, 'mean_word_length': 5.185567010309279, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Whatever happened to expanded access?


 People living with AIDS (PWAs) have dramatically changed the way new pharmaceuticals are introduced and researched in the United States. Expanded access is the general term for pharmaceutical company programs that distribute new drugs prior to formal approval from the Food and Drug Administration (FDA). In 1996, expanded access gave way to marketing by pharmaceutical companies. AIDS advocates are calling for the reintroduction of compassionate drug programs; activists are urged to unite and work toward early access for all people living with HIV/AIDS.
